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RHEUMATOID ARTHRITIS AND LYMPHOMA: THE ROLE OF DISEASE-
MODIFYING ANTI-RHEUMATIC DRUGS 
 
JORDAN DETRICK 
 
 
ABSTRACT 
 
A well-functioning immune system is of paramount importance in 
preventing lymphomagenesis. Both immunostimulation, which causes excessive 
cell turnover and increased potential for mutations, and immunosuppression, 
causing a decreased ability to monitor and halt aberrant cell proliferation, have 
been implicated in cancer development. 
Autoimmune diseases are characterized by excessive activation of 
lymphocytes due to a dysregulated response to self-antigens. The treatments for 
autoimmune disease therefore share a common goal of immunosuppression. 
While treatments have become better-targeted to specific inflammatory 
pathways over the last 30 years as opposed to general immunosuppression, there 
remains a high risk of hematologic malignancy for patients with autoimmune 
disease relative to the general population. There are numerous types of 
autoimmune disease, as well as much heterogeneity within each diagnosis from 
patient to patient. The focus of this thesis is Rheumatoid Arthritis (RA), a 
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strikingly common disease affecting 0.5-1.0% of the world population and 
characterized by debilitating, painful, joint-deforming symptoms and difficulty 
in achieving remission. [1] Therapeutic intervention often necessitates a trial and 
error approach and various combinations of drugs, in the same way cocktails of 
chemotherapeutic drugs are tailored to treat cancers due to their heterogeneity. 
Drugs for the treatment of autoimmune diseases are collectively known as 
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and were only first widely 
used for the treatment of RA in the 1980s. This short history of widespread use, 
along with the great variability in manifestation of disease and treatment course, 
has historically limited the ability of observational studies to determine the safety 
of DMARDs in terms of malignancy risk. Only in the past few years has enough 
information been available, drawn mostly from national healthcare databases in 
several countries, to enable strong conclusions about the effects of DMARDs on 
malignancy risk. This thesis aims to provide a comprehensive review of the most 
recent and well-designed studies regarding currently available DMARDs for RA 
and their effects on the risk of lymphoma. 
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INTRODUCTION 
The molecular and cellular pathways of inflammation in autoimmunity share 
some features with aberrant B and T cell activation during growth and 
development of lymphomas (lymphomagenesis). The complexity of these 
mechanisms remains not well understood. Recent convincing evidence has 
implicated one such shared feature, providing a potential therapeutic target in a 
cytokine, BAFF (B Cell Activating Factor Belonging to the TNF Family), which 
plays a role in both lymphoma and experimental arthritis in laboratory animals. 
[28] BAFF is critical in B cell development at the stage of eliminating self-reactive 
cells and its dysregulation in mice leads to autoimmune disorders. The study by 
Sutherland et al. [28] found that BAFF-transgenic mice have an increased risk of 
lymphoma, and BAFF seems to have a protective effect against apoptosis of 
malignant cells. Blocking of BAFF by engineered antibodies reduced symptoms 
and mortality from both arthritis and lymphoma. It was also found that BAFF 
serum levels are higher in human patients with some autoimmune diseases as 
well as in patients with some lymphomas and lymphoproliferative disorders. 
The molecular and cellular associations between rheumatoid arthritis and 
lymphoma are all the more evident in the fact that some newer therapies (namely 
Rituximab) are effective against both. 
I. Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease three times more 
prevalent in women than men and increasingly prevalent with age, perhaps 
pointing to a hormonal influence in addition to genetic and environmental risk 
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factors. Approximately 50% of the risk for RA is attributable to genetic factors 
and more than 30 genetic loci have been implicated. [1] Although these suspect 
genes have been identified, the pathogenesis of their influence in developing RA 
remains unclear. Smoking remains the most highly-correlated environmental risk 
factor, where smoking-related tissue necrosis is thought to be of influence in the 
onset of excessive inflammation and immune response to self-antigens. [2] 
 Rheumatoid arthritis also increases the risks of several other comorbidities 
in addition to lymphoma including cardiac disease, depression, and other 
malignancies. Extra-articular manifestations include vasculitis and ophthalmic, 
neurologic, and cutaneous complications, which further increase the 
symptomatic burden for patients. The most common extra-articular 
manifestations and comorbidities, as well as the criteria used for diagnosis and 
disease severity assessment are shown in Table 1. [1] 
 Fortunately, it is believed that the severity of RA may be decreasing in the 
overall population, with lower rates of joint replacements and hospital 
admissions for RA, as well as lower recorded erythrocyte sedimentation rates (a 
common measure of severity of inflammation) and a lower incidence of 
vasculitis. [1] This overall decrease in severity is suspected to be due to better 
treatment strategies, and particularly better use of conventional DMARD 
treatment, because the beginning of the decline in severity preceded the use of 
biologic DMARDs. An outline of the typical RA treatment progression, including 
relative costs associated, is presented in Figure 1. [1] 
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Disease activity 
assessments 
Extra-articular disease  Comorbidities 
Joint counts 
(tender and 
swollen joint 
counts) 
 
Global 
assessment 
(doctor and 
patient) and pain 
score 
 
Laboratory 
(erythrocyte 
sedimentation 
rate and C-
reactive protein) 
 
Disability 
 
Fatigue 
 
Radiologic 
damage 
Pulmonary 
Nodules 
Pleural effusion 
Fibrosing Alveolitis 
 
Ocular 
Keratoconjunctivitis 
sicca 
Episcleritis 
Scleritis 
 
Vasculitis 
Nailfold 
Systemic 
 
Cardiac 
Pericarditis 
Pericardial effusion 
Valvular heart disease 
Conduction defects 
 
Neurological 
Nerve entrapment 
Cervical myelopathy 
Peripheral neuropathy 
Mononeuritis 
multiplex 
 
Cutaneous 
Palmar erythema 
Pyoderma 
gangrenosum 
Vasculitic rashes 
Leg ulceration 
 
Amyloidosis 
Cardiovascular 
Myocardial 
infarction 
Heart failure 
Stroke 
Peripheral vascular 
disease 
Hypertension 
 
Cancer 
Lymphoma and LPD 
Lung cancer 
Skin cancer 
 
Infection 
 
Depression 
 
Gastrointestinal disease 
 
Osteoporosis 
 
Psoriasis 
 
Renal Disease 
 
Table 1. Disease assessment measures, extra-articular disease manifestations, 
and comorbidities of Rheumatoid Arthritis. Adapted from source: Scott DL, 
Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094-
108. 
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Figure 1. Standard RA Treatment Progression. From source: [1] Scott DL, Wolfe 
F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094-108. 
PubMed PMID: 20870100. 
 
  
II. RA-Related Lymphoma 
Patients with RA are at an increased risk of certain types of lymphoma 
compared to the general population, particularly diffuse large B-cell lymphoma 
(DLBCL) but also including several other types of Non-Hodgkin Lymphoma 
(NHL). [4] The prevalence of the subtype DLBCL is particularly interesting, in 
one study representing 56% of all NHL compared with only 30% of NHL in the 
general population. [3] This suggests that the specific pathways of immunologic 
cell proliferation in RA are in some way linked to and perhaps responsible for 
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the oncogenic mutations underlying this increased proportion of a particular 
lymphoma subtype. 
 Rheumatoid arthritis patients have impaired control of Epstein Barr Virus 
(EBV) infection, with up to a ten-fold increase in viral load compared to the 
general population [29]. EBV has long been implicated in some types of 
lymphoma, particularly in post-transplant patients undergoing 
immunosuppressive therapy. [30] The lack of T-cell surveillance in 
immunosuppressed patients allows for uncontrolled proliferation of the viral 
host cells, B cells, and sometimes leads to malignant transformation to a 
lymphoproliferative disorder or lymphoma. The immunosuppressive therapy 
given to patients with rheumatoid arthritis has a similar effect on disabling T cell 
control of EBV infection, and may be one mechanism by which lymphoma arises 
in these patients. 
 EBV is an extraordinarily common virus, estimated to infect around 90% 
of the adult population worldwide. [35] The virus largely remains in its latent 
phase and is therefore asymptomatic for most people. The danger of EBV lies in 
its occasional ability to transform its host cell, the B lymphocyte, into a 
continuously proliferating and cancerous cell line. EBV was therefore declared a 
class I carcinogen in the 1990s by the World Health Organization. This 
transformative ability is enhanced when patients are immunosuppressed, 
whether by disease or therapeutically, allowing opportunistic EBV-related 
cancers to arise more frequently. [35] Thus far, there is no vaccine nor adequate 
treatment available for latent EBV infection.  
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 Auto-antibodies known as rheumatoid factor (RF) are prevalent in the 
serum of patients with RA and particularly so if they have severe disease 
manifestations. RFs recognize the Fc portion of IgG and may in fact be 
responsible to some degree for activating B cells harboring latent EBV, according 
to a study from the Journal of Virology. [5] Increased B cell activation was 
induced by RF in vitro, which caused phosphorylation of the tyrosine kinases 
associated with the B cell receptor (BCR) and an enhanced influx of calcium in 
the B cell lines, both necessary steps in lytic EBV activation. This effect was 
limited to synovium-derived RF and was not observed with low affinity RFs 
derived from peripheral blood mononuclear cells, which may indicate that high 
levels of joint inflammation and synovial RF play a more important role in 
inducing activation of latent EBV and thus activation of B cells. [5] Excessive 
activation of B cells is theoretically likely to increase the chances of lymphoma 
due to the increased opportunity for mutations in rapidly proliferating B cell 
populations. 
 One analysis of shared cellular and molecular patterns in RA and 
lymphoma suggested that RA itself could be considered a lymphoproliferative 
disease precursory to lymphoma. [6] For RA to be tantamount to a malignancy 
would require the presence of clonality, which has been detected in the form of 
clonal plasma cells in the bone marrow and synovium of RA patients. B cells 
have the propensity to contribute to the inflammation and joint destruction seen 
in RA through multiple mechanisms including antibody production, cytokine 
modulation, antigen-presentation, and activation of CD4+ T cells. The authors of 
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the above-mentioned study suggest that B cells therefore may be the primary 
immunologic instigators of the onset of RA, and the clonal populations of B cells 
arising from this at the site of inflammation may be responsible for 
lymphomagenesis. 
 
III. DMARDs 
RA and most other autoimmune diseases are typically treated with disease-
modifying anti-rheumatic drugs (DMARDS) of which there are several classes 
with variable mechanisms of action. The targets of these DMARDs range from 
inhibition of purine metabolism (methotrexate) to a targeted interference in 
immune cell activation signaling (rituximab). [7] [8] Their general common goal 
is to reduce systemic inflammation, and their targets are typically in reducing 
cytokine production, availability and interaction with receptors. The use of 
multiple DMARDs and the length and strength of their administration depends 
on disease severity, therefore it has been difficult to discern if adverse effects are 
due to underlying disease activity or an iatrogenic effect of inappropriate 
therapy. [4] The similarities in immune system hyper-activation and cell 
proliferation between rheumatoid arthritis and lymphoma complicate the 
determination of molecular origins of autoimmune-related lymphoproliferative 
disease. The use of DMARD therapy can further obfuscate the origin of 
lymphomagenesis should it arise, as it does more frequently in those with 
autoimmune disorders than in those without. 
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SPECIFIC AIMS 
Specific aims of the following thesis include:  
1. Consolidate and analyze the available literature on recent observational 
studies and clinical trials of various DMARDs and their effects on the risk 
of lymphoma in patients with RA.  
2. Compare methotrexate, TNF inhibitors, rituximab, corticosteroids and 
other DMARDs as treatments for RA and their roles in prevention or 
indirect induction of lymphomagenesis 
3.  Analyze best treatment modalities for RA patients with comorbidities and 
prior malignancies based on minimizing risk from a personalized 
medicine standpoint 
4. Discuss future directions of research and therapies currently in 
development 
 
 
  
 9 
 
LIMITING CUMULATIVE BURDEN OF DISEASE 
The majority of large, well-designed and unbiased studies to date have 
concluded that the severity and course of an underlying autoimmune disease has 
a much stronger correlation with risk of malignancy than does 
immunosuppressive treatment with DMARDs. The risk of lymphoma has been 
found to correlate heavily with a measure of the overall severity of the 
autoimmune disease, termed cumulative burden of disease, which is based on 
assessments of erythrocyte sedimentation rate (ESR), number of articular joints 
involved by disease, and other clinical manifestations of chronic inflammation 
over time. The greatest evidence thus far has come from a long-term 
retrospective study by the Swedish research team Baecklund et al., in which 
patients were stratified into categories based on severity of RA and 
retrospectively studied over a long period from 1964 to 1995. [4] The study 
showed that those with the highest cumulative disease burden over that 30-year 
span had a 70-fold increase in risk of lymphoma relative to the general 
population. The majority (70%) of the entire patient population had been treated 
with DMARDs, but the study also showed that even those who had not received 
DMARD treatment had the same risk profile according to cumulative disease 
severity, and that DMARD therapy added no additional risk. This study, 
however, did not include any patients treated with tumor necrosis factor 
inhibitors (TNFi), which were only introduced for widespread use in the 1990s. 
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ADVERSE EFFECTS 
The increased risk of malignancy in RA patients with a history of prior 
malignancies remains a major concern with DMARD therapy due to 
immunosuppression. Tumor necrosis factor plays a major role in mediating 
normal immune inflammatory pathways, and is problematic in excess quantities 
in autoimmune diseases, making it a compelling target for therapy by a relatively 
new class of drugs, the tumor necrosis factor inhibitors (TNFi). TNFi have been 
contraindicated in patients with prior malignancies according to a few limited 
studies, therefore the American College of Rheumatology currently suggests that 
TNFi not be used in patients with a history of malignancy less than 5 years prior 
to treatment. [9] It has been difficult to conclusively determine the risk of a 
subsequent malignancy with TNFi because patients with prior malignancies are 
usually excluded from trials in order to minimize risk. 
EBV lytic activation is an additional major adverse effect of 
immunosuppressive therapy, particularly in RA patients who already have 
increased EBV viral loads due to innate immune dysfunction. The Swedish study 
by Baecklund et al. found what they described as an unremarkable number of 
EBV-positive lymphomas (12%), which is roughly equal to the number of EBV-
positive lymphomas in the general population. [4] This may however suggest 
that patients in an immunocompromised state, such as those receiving DMARD 
therapy for autoimmune disease, have an increased risk of lymphoma due to 
lytic EBV activation in the absence of normal immune protection. It was noted by 
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both the Swedish study and a Japanese study by Ichikawa et al. that there have 
been several cases of regression of lymphoma following withdrawal of the most 
common DMARD immunosuppressive therapy, methotrexate. [4] [9] This would 
indicate that this drug may have a role in allowing reactivation of latent EBV, 
thereby allowing lymphomagenesis via immunosuppression. This is 
contradictory to the theory that lymphoma in RA patients arises predominantly 
as a result of the state of high, continual immune stimulation. The evidence 
appears to point to both processes of lymphomagenesis in different cases. The 
risk of methotrexate-associated lymphoma also seems to be elevated in 
populations where EBV-associated lymphoma is generally more common, 
specifically in Asian countries. [10] Of note, the subtypes of lymphoma 
associated with EBV differ from subtypes not associated with EBV. Further 
analysis of the spectrum of lymphoma subtypes arising in patients undergoing 
different treatment modalities for RA would be of use, but has not yet been 
comprehensively reported. 
 It has been proposed that RA itself may arise as a result of antigenic cross-
reactivity between EBV epitopes and self-antigens. In a study of 627 patients RA 
patients, 45% had anti-citrullinated peptide antibodies (ACPA) against a 
citrullinated EBV peptide (which are commonly post-translationally modified in 
this way). [10] Serum levels of ACPA are strong positively correlated indicators 
of RA severity. ACPA have also been recently shown to mediate joint destruction 
by binding to immature osteoclasts and promoting their activation to bone-
resorbing mature osteoclasts. [11] It is thought that ACPA are first produced in 
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response to the citrullinated EBV epitopes in response to viral infection, and 
these antibodies cross-react with self-antigens thus producing the autoantibodies 
responsible for the onset of RA. EBV infection in RA patients could therefore 
theoretically further exacerbate the symptoms of RA by inducing the production 
of more autoantibodies. 
 In studies of lymphomas in patients without RA or underlying 
autoimmune disease, it has been found that lymphomas can be traced to 
triggering by certain antigens, be they viral or self-antigens, and by aberrant 
signaling through the B cell receptor (BCR), which are also common pathways 
shared by autoimmune disease. [12] Since B cells routinely undergo somatic 
genetic modifications as part of their normal function (class-switching, somatic 
hypermutation, and VDJ recombination) they are very much at risk for 
oncogenic mutation, particularly in a state of high activation of B cells due to an 
autoimmune disease. Chronically active BCR signaling due to both 
overabundant antigenic stimulation and activating mutations within the BCR 
signaling pathway have been implicated in lymphomagenesis in the general 
population, and is likely to be seen with great frequency among RA patients with 
lymphoma as well. This chronic activation in turn leads to further proliferation 
and clonal expansion of B cells, thus allowing even greater opportunities for 
oncogenic mutation. These have been proposed as the mechanisms underlying 
the innate increased risk of lymphoma for patients with RA, particularly for 
those with the highest disease severity and therefore the most B cell activation. 
[12] Unfortunately, it has not yet been experimentally possible to prove nor 
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disprove this mechanism of lymphomagenesis in autoimmune disease, therefore 
it remains only a plausible theory. 
 Additional evidence for this theory lies in the fact that inflammatory 
conditions aside from frank autoimmune disease have been found to lead to site-
specific lymphomagenesis, including chronic long-term pyothorax, chronic 
osteomyelitis, foreign body reactions to metallic implants, and chronic ulcers. 
[13] It is thought that IL-10, an immunosuppressive cytokine released by chronic 
inflammatory cells, inhibits T cells from restraining EBV-infected cells and 
therefore allows their oncogenic transformation, particularly to become DLBCL.  
 A specific cytokine, APRIL , has been implicated in lymphomas arising in 
patients with autoimmune disease. This cytokine is necessary for B cell 
proliferation and development, has been found exclusively in DLBCL rather than 
other types of lymphoma, and is present in higher proportion in RA patients 
with more severe disease as opposed to those with less severe disease. [13] This 
suggests a role of this cytokine- produced excessively in the pathways of 
autoimmune inflammation- in specifically directing lymphomagenesis of the 
DLBCL type, and therefore critically important to the study of lymphoma in RA 
patients. 
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DMARD COMPARISON 
 Given that numerous DMARD therapies are now available for the 
treatment of RA, it is useful to compare their malignancy risks in an effort to 
inform best treatment practices. Many studies have been done in the past decade 
to determine if these drugs have any impact on increasing or reducing patients’ 
lifetime risk of lymphoma, since it remains a major comorbidity of RA. 
Malignancy risk ratios derived from the examined studies are presented here in 
Table 2.  
DMARD [source cited] Treatment Group Control Group 
Methotrexate [4] 
 
OR 0.7 (95% 0.3-1.6) Untreated RA patients 
Tumor Necrosis Factor 
Inhibitors (Adalimumab, 
Infliximab, & Etanercept) 
[19] 
 
HR 1.00 (95% CI 0.56-
1.80) 
Patients treated with 
conventional DMARDs 
Golimumab [11] 
 
SIR 1.08 (95% CI 0.82–
1.40) 
General US population 
Abatacept [26] 
 
OR 0.73 (95% CI 0.42-
1.17) 
Placebo group + 
background therapy 
Tocilizumab [12] 
 
OR 1.09 (95% CI 0.63-
1.74) 
Placebo group + 
background therapy 
Tofacitinib [27] 
 
OR 0.85 (95% CI 0.70-
1.02) 
Placebo group + 
background therapy 
Rituximab [23] 
 
SIR 1.07 (95% CI 0.88–
1.29) 
General US population 
Oral Corticosteroids [13] 
 
OR 0.6 (95% CI 0.4–0.9) Untreated RA patients 
Intraarticular 
Corticosteroids [13] 
OR 0.4 (95% CI 0.2–0.6) Untreated RA patients 
Table 2. Malignancy Risk Ratios of DMARD Therapies. Adapted from sources: 
[4] [19] [11] [26] [12] [27] [23] [13] OR=Odds Ratio; HR=Hazard ratio; 
SIR=Standardized Incidence Ratio; CI=confidence interval. Values less than 1 
indicate a decreased risk, values greater than 1 indicate an increased risk relative 
to the control group, if 1.0 falls outside the confidence interval. 
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METHOTREXATE 
Methotrexate is the most commonly used DMARD and is considered the 
gold standard of RA therapy, owing to its efficacy in achieving remission in 30% 
of patients, reducing symptoms in up to 75% of patients, and its cost-
effectiveness. [1] [14] Its mechanism of action is via cellular uptake and induction 
of adenosine release, primarily affecting mononuclear cells and neutrophils and 
producing a systemic reduction in inflammation. [15] 
A Japanese study published in 2013 showed an interesting correlation 
between EBV-positive lymphomas and methotrexate therapy. [9] While small in 
number of cases, this study showed that 60% of the 102 patients who developed 
lymphoma had EBV-positive lymphoma, and 59% showed regression after 
withdrawal of methotrexate. EBV-positivity was correlated with this incidence of 
regression, and it is noteworthy that subtypes other than DLBCL most 
commonly fit this scenario. This indicates that RA patients with EBV-positive 
lymphoma, particularly subtypes other than DLBCL, may be more likely to 
respond to MTX withdrawal as first-line therapy. This also alludes to the theory 
that MTX may have some influence in allowing (via immunosuppression) or 
even inducing these other subtypes of lymphoma in some patients. RA patients 
have been shown to have a higher than normal viral load of EBV due to a genetic 
deficiency of CD8+ cytotoxic T cells, and methotrexate further suppresses the 
ability of T cells to control viral load. [9] Regression of lymphoma upon 
withdrawal of DMARD therapy (sulfasalazine, MTX, and azathioprine) was also 
seen in another study by Baecklund et al., although only in a handful of cases, 
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none of which were EBV positive. [13] Although methotrexate treatment does 
not correlate with a general increase in risk of developing lymphoma [21], the 
several reported cases of lymphoma regression upon its withdrawal would 
suggest that this therapy plays some role- at the very least permissive- in 
lymphoma development.  
 A study of the incidence of p53 mutations in RA-related lymphomas 
found that those treated with methotrexate were less likely to have p53-mutated 
lymphoma (15.6%) and thus a better prognosis than those who had not been 
treated with methotrexate (47.6% with p53 mutations). [16] However, it was also 
found that the duration of time between the onset of RA and that of 
lymphoproliferative disease was longer for patients who had not been treated 
with MTX (198 months, versus 134 months for those with prior MTX therapy). 
There was no difference in the subtype distribution between the MTX and non-
MTX groups. This potentially suggests both that MTX may again have some 
permissive or inductive role in lymphomagenesis, but also it is more likely to 
allow for lymphomas with oncogenic mutations other than p53 mutations, and 
thus these patients have better prognoses. 
 In a study of a less-common RA-related lymphoma, T/NK cell lymphoma, 
methotrexate withdrawal was sufficient to induce lymphoma regression in 7 of 8 
patients with this lymphoma subtype. [17] This study also showed that EBV 
infection was much more evident in patients treated with MTX (46%) than those 
not treated with MTX (7.7%), in both DLBCL and T/NK cell lymphoma. The 
authors proposed that withdrawal of MTX was therapeutic by means of allowing 
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the immune system to recover from iatrogenic suppression and therefore control 
active EBV infection. 
 Unfortunately, 20-40% of patients with RA have refractory disease or are 
unable to tolerate the gold standard of MTX therapy. [18] Therefore there 
remains a need for study of the effectiveness and safety of newer and more 
effective targeted therapies.  
TUMOR NECROSIS FACTOR INHIBITORS 
Tumor necrosis factor itself was studied as a potential therapy for 
malignancy in laboratory animals, hence its name, however TNF was found to 
have both tumor-suppressive and tumorigenic activity, and has seen limited use 
for the treatment of overt malignancies. TNF inhibitor therapies are among the 
first forms of the biologic class DMARDs, which are genetically engineered 
antibodies that exert their effects through targeting specific molecular pathways 
of inflammation. In earlier studies, TNF inhibitors were initially deemed to have 
an influence on raising the risk of lymphoma, however this has been 
contradicted by larger recent studies. [11] The increased incidence of lymphoma 
with TNFi is now widely considered to be more likely due to the fact that 
patients with more severe RA are likely to be treated with TNFi, usually as a 
second-line therapy for refractory disease after or in combination with 
methotrexate. 
Natural killer (NK) cells play a role in preventing lymphoma by their 
immunosurveillance mechanisms, therefore a study was done to determine the 
effect of TNFi on NK cells. [17] NK cells were assessed ex vivo for their 
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cytotoxicity against Non-Hodgkin’s lymphoma cell lines, and were found to 
have reduced activation and impaired function when treated with TNFi versus 
treatment with methotrexate alone. NK cell activity and effectiveness against 
lymphoma was determined by measures of degranulation and interferon-gamma 
secretion, which are the primary indicators of cytotoxicity by NK cells. TNF 
receptor type 1 signaling is thought to be necessary for proper functioning of NK 
cells, and therefore it follows that the result of TNFi would be some inhibition of 
NK cell activity. This suggests that while TNFi may prevent lymphomagenesis 
through their dampening of excessive immunologic activity in RA, they may also 
be permissive to lymphoma by impeding immunosurveillance by NK cells. In 
this study, no difference was observed between etanercept and the other 
available therapeutic monoclonal antibodies, infliximab and adalimumab, in 
their effects on NK cells. Additionally, two lymphoma cell lines were compared 
under these conditions, one EBV positive and the other EBV negative, and the 
same results were observed for both, suggesting that NK cells are equally prolific 
in combatting EBV-positive and EBV-negative lymphomas, and TNFi interfere 
with their function in both cases. Interestingly, neither TNF nor interferon-
gamma alone were sufficient to produce apoptosis in the lymphoma cells, 
therefore it must be presumed that TNFi have an immunosuppressive effect on 
NK cells themselves, and not merely on these inflammatory cytokines. The 
mechanism by which this inhibition occurs is yet unclear, however the authors of 
this study propose that it is likely via inhibition of TNF receptor type 1 signaling 
or via inhibition of secretion of interferon-gamma, whose role is to make target 
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cells more susceptible to NK cell destruction through stimulation of expression 
of an NK-cell ligand, ICAM-1, on these target cells. [17] 
A study of the British Society for Rheumatology Biologics Register for 
Rheumatoid Arthritis indicated that at a treatment duration up to 5 years, TNFi 
therapy conferred no additional risk of lymphoma over that of other DMARDs. 
[19] While this study included over 120,000 patient years of observation, the 
patient years were heavily weighted by number of patients but relatively short in 
time span. It will be critical to study if there is any increased risk with longer-
term use, as these are still relatively new drugs and will likely be prescribed for 
continuing disease control throughout lifetimes, and because lymphoma risk is 
also generally correlated with age. The patient population receiving TNFi in this 
study was younger compared to that receiving traditional DMARD therapy, and 
while no significant risk difference was evident once the findings were adjusted 
for this age difference, this is essentially a projection from data gathered over a 
relatively short time span for young patients and it will be important to continue 
monitoring lymphoma risk of long-term TNFi therapy. TNF inhibitors have 
additionally been implicated in a rare and aggressive type of lymphoma, 
hepatosplenic T cell lymphoma, but the rarity of this type of lymphoma has 
precluded conclusive evidence of this linkage. [3] 
The distribution of lymphoma subtypes, however, is seemingly 
unchanged between TNFi and traditional DMARD therapy. Since this was a 
study of a national patient registry in the UK, it is worth noting that UK 
guidelines for administration of TNFi recommend their use only for patients who 
 20 
fall into a high-severity category of cumulative disease burden and should have 
refractory disease which has already been unsuccessfully treated with 
methotrexate and at least one other DMARD. [19] This suggests that the TNFi 
cohort of patients generally had more severe RA and therefore an implicitly 
higher risk of lymphoma regardless of therapy. The finding that the risk of 
malignancy was no greater than that of other DMARDs was based on an 
adjusted hazard ratio accounting for severity of underlying autoimmune disease. 
The researchers of this study also conceded that continuing follow-up of a larger 
population is necessary to determine if long-term use or cumulative dose of TNFi 
has an influence on malignancy risk. 
Reassuringly, one study did find that adalimumab, infliximab, and 
etanercept had no effect on EBV viral load or on EBV-specific T cell population 
size compared to baseline, suggesting that these therapies are at least not likely 
to induce EBV-driven lymphomas. [11] 
Golimumab, a less-commonly used TNFi, was shown to have the same 
risk profile as other TNFi therapies (SIR 1.07), however in higher doses (100 mg) 
the malignancy risk significantly increased (SIR 7.71). [20] This may suggest that 
lymphoma risk is dose-dependent for TNFi therapy, either uniquely with 
Golimumab or perhaps applicable to all TNFi, and could be another explanation 
for the seemingly increased risk of lymphoma other than the hypothesis that a 
patient population with more severe disease is more apt to undergo TNFi 
therapy. Dose escalation due to unresponsiveness of severe disease could also 
account for the increased risk among patients receiving a higher dose, but it is 
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not possible to determine which scenario is responsible based on current data 
and therefore further study is warranted. 
A French study in which the three most common TNFi (adalimumab, 
infliximab, and etanercept) were compared collectively with conventional 
DMARDs suggested that there was no difference in TNFi versus DMARD 
therapy for lymphoma risk, however there was a higher risk with adalimumab 
and infliximab than with etanercept. [21] These TNFi differ in form and function 
in that adalimumab and infliximab are monoclonal antibodies which exert their 
effects on both types of TNF receptors, while etanercept is a genetically 
engineered part-antibody/part-receptor soluble protein which exerts its effects 
on one type of TNF receptor but not the other. [11] The researchers of this study 
were not able to compare each of these three TNFi therapies specifically against 
one another with conclusive results, however, due to the fact that many patients 
switched from one to another of the three TNFi during the course of therapy. 
This also suggests that some patients may have had more severe RA which was 
at times unresponsive to TNFi therapy, and may account for the observed 
elevation of malignancy risk. 
RITUXIMAB 
Rituximab was first approved for use against Non-Hodgkin’s lymphoma 
in 1994. Its mechanism of action is systemic depletion of B cells by targeting the B 
cell marker CD20. Rituximab has since proven very effective against B cell 
malignancies and has been incorporated into first-line therapy as well as for use 
in refractory and relapsed disease. [22] Rituximab has also shown dramatic 
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improvements in patients with EBV-related lymphoproliferative disorders 
following transplants. [31] Its high degree of effectiveness in treating B cell 
lymphomas thus far makes it a promising single-intervention therapy for 
patients with both RA and lymphoma. 
In 2006, rituximab was approved for use in patients with RA without any 
history of lymphoma, when disease is refractory to traditional DMARDs. [22] 
This has been reassuringly effective, and tolerated just as well as its use for 
lymphoma therapy. Rituximab has been found to confer no increased risk of 
lymphoma. [8] RA patients treated with rituximab are more likely to have severe 
RA, and therefore a baseline high risk of lymphoma. Rituximab has preliminarily 
shown promise in abating the risk of lymphoma in RA patients, and is indicated 
for patients with prior malignancies. [6] [8] An observational study of 11 years of 
clinical trials of rituximab for RA showed no increased risk of any type of 
malignancy regardless of treatment course or duration compared to patients with 
RA not treated with rituximab. [23] 
 A French study of a small cohort of 186 patients receiving rituximab 
therapy for RA showed zero new hematologic malignancies at a mean follow-up 
of 22.3 months, including 6 patients who had prior lymphomas which remained 
in remission. [24] The authors of this study suggested that this may be due to the 
fact that rituximab does not have the same prolonged immunosuppressive 
effects of other DMARD therapies. They also proposed that the results of their 
study suggest a protective effect of rituximab against lymphoma in RA patients, 
but conceded that the small size and short duration of the study warrants further 
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confirmation. It was not possible to compare a control group who had never 
received DMARD therapy, since most patients had at some time been exposed to 
other DMARDs prior to rituximab therapy. The complete absence of hematologic 
malignancies in this group is however reassuring, given than rituximab is 
generally used for RA patients with severe refractory disease who are most at 
risk of lymphoma. 
CORTICOSTEROIDS 
 One study by Hellgren et al. concluded that an oral steroid course of less 
than 2 years produced virtually the same risk profile of lymphoma for patients 
with RA (0.87), but more interestingly that an oral steroid course of more than 2 
years produced a decreased risk of lymphoma (OR 0.43), in effect producing a 
30% reduction in risk with oral steroids. [25] Figure 2 shows the decreased odds 
ratios of developing a malignancy for all quartiles of RA disease activity with 
steroid therapy compared to patients not treated with steroids. This is further 
unexpected considering that 74% of patients had a disease activity score in the 
highest quartile, and the reduction of risk held true for patients in every quartile. 
Additionally, patients who received intraarticular steroid injections also showed 
a decreased risk of lymphoma, as long as the steroid injections were consistently 
used in the case of symptomatic flares. This study was also able to stratify risk 
differences based on subtypes of lymphoma, and found the strongest association 
between risk reduction and subtype in DLBCL, the most common subtype of 
lymphoma for RA patients. This may suggest that corticosteroids are particularly 
effective in targeting whichever particular pathways are shared between the 
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disease mechanisms of RA and lymphomagenesis. The authors suggest one 
possibility for the mechanism of risk reduction in the apoptotic properties of 
corticosteroids on immunologic cells. High-dose corticosteroids are frequently 
used in concert with chemotherapy for hematologic malignancies for just such a 
purpose, and this effect may also be protective against lymphoma in patients 
treated for RA. The authors concede that the lower steroid doses commonly used 
in RA treatment may not be sufficient to produce this effect, and that this theory 
is at present speculative. Another potentially confounding influence they 
propose is that patients who received swift steroid treatments, particularly 
intraarticular injections, are more likely to be receiving generally better 
rheumatologic care, and therefore their autoimmune disease may be better 
managed and their malignancy risk profile lowered as a result. [25] 
 Unfortunately, the use of corticosteroids confers considerable risk of 
comorbidities including osteoporosis and serious infections, therefore long-term 
use of steroids for treatment of RA is inadvisable as these risks seem to outweigh 
their benefits. [1]  
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Figure 2. Interaction Between Steroid Intake and Quartiles AUC. AUC=area 
under the curve, an assessment of disease severity. Disease severity increases left 
to right. From source: [25] Hellgren K, Iliadou A, Rosenquist R, et al. Rheumatoid 
arthritis, treatment with corticosteroids and risk of malignant lymphomas: 
results from a case–control study. Annals of the Rheumatic Diseases 2010;69:654-
659. 
  
 
OTHER DMARDs 
Tocilizumab, a relatively new DMARD with a novel target in the 
inflammatory cytokine IL-6, has been shown in a small study to carry no 
increased risk of malignancy, though the authors concede that longer-term 
follow-up of a larger patient population is advisable for more confidence in this 
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conclusion. [12] IL-6 is critical for viral immunosurveillance by stimulating T 
cells. However, tocilizumab was surprisingly found to decrease EBV viral load, 
and although the patient population was very small, most of the patients 
observed had progressively decreasing EBV virus loads, and at a 4-year follow-
up none of the 5 patients remaining in the study had any detectable EBV DNA, 
which is quite surprising given that patients with RA typically have much higher 
EBV viral load than the general population. None of the patients who received 
tocilizumab developed lymphoma over the course of the study, but this 
conclusion should be regarded cautiously given the very small population size 
and further study should be conducted. 
 Abatacept is the first drug of its kind, targeting a pathway of T cell 
activation via CD80, CD86 and CD20 cell receptor costimulatory pathways. A 
2013 study of 8 years of abatacept clinic trials found an incidence ratio of 
malignancy similar to that of RA patients undergoing other DMARD therapies, 
and concluded that abatacept conferred no additional risk of lymphoma. [26] 
However, an increase in other adverse events including respiratory, infectious, 
and musculoskeletal complications in patients with underlying comorbidities 
(COPD and diabetes) may preclude the widespread use of this therapy in RA 
patients pending further study. 
 Tofacitinib, also a first of its kind therapy, is a janus kinase inhibitor, 
exerting its effects via interruption of inflammation mediated by the cellular 
signaling pathway known as JAK (janus kinase). A 2016 study of the clinical 
development program for tofacitinib concluded no increased risk of malignancy 
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compared to other cohorts of RA patients. [27] This conclusion could possibly be 
dose-dependent, given that the study showed an increased number of all 
malignancies including lymphoma in a treatment group receiving a higher dose 
in phase III clinical trials. 
 Gold derivatives and ciclosporin (cyclosporine) have been used 
sporadically in the past as DMARD therapy and do not increase the risk of 
lymphoma, but their use has widely been discontinued due to toxicity. [1] 
Several other DMARDs historically have been used in the treatment of RA and 
most do not confer any increased risk of lymphoma, including antimalarial 
agents (hydroxychloroquine), cyclophosphamide and sulfasalazine, but these are 
no longer frequently used due to toxicity or inferior efficacy in comparison to 
other therapies. Azathioprines have been used alone and in combination with 
methotrexate, however these have been found to increase the risk of lymphoma 
and are therefore contraindicated in most cases. [4] 
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CONCLUSIONS AND FUTURE DIRECTIONS 
Rituximab and corticosteroids have thus far shown the most promise in 
reducing risk of lymphoma while treating RA symptoms, but their tolerability 
may preclude their use in the same widespread manner of other DMARDs. 
Future drug development will most likely tend toward targeting specific cellular 
markers and receptors in the same way rituximab does, in the hope that one or a 
few drugs in particular will also have an influence on reducing the risk of 
lymphoma by interrupting the shared immunostimulatory pathways of RA and 
lymphoma. Unfortunately, corticosteroids have such detrimental systemic effects 
in long-term and high-dose use that they will likely not be pursued as a first-line 
treatment for RA patients at risk of lymphoma. 
The cytokine composition in RA can differ from patient to patient, and it 
has been suggested that assessing cytokine profiles on an individual basis could 
be helpful in distinguishing RA from other autoimmune disorders earlier, 
allowing earlier aggressive treatment and potentially more success. [32] 
Currently only a few biomarkers are assayed in RA assessment, including RF 
and acute phase reactants in the form of an ESR test, however they have not been 
sufficient to determine the prospective course of disease or the best first-line 
therapies for individual patients, which is something that cytokine biomarker 
assays may afford in the future. Brzustewicz et al., in their analysis of the future 
potential of cytokine profiling, proposed that it would improve personalized 
therapy by enabling more accurate tracking of response to drugs over time, and 
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helping to identify patients not responsive to a therapy earlier so that they may 
be switched to another drug. [32] This type of assay needs further development, 
because at present it is difficult to correlate cytokine concentration with their 
biological activity, and there is so much variability between patients that it will 
take time to produce an assay adequate to screen all patients. 
If cumulative burden of inflammation is the main determinant of 
lymphoma risk, and DMARD therapy reduces cumulative burden of 
inflammation, it might be expected that DMARD therapy would reduce the risk 
of lymphoma rather than only produce the same risk profile. All of the 
aforementioned DMARDs carried similar risk of lymphoma compared to 
patients with RA not undergoing therapy, except for corticosteroids which 
decreased the risk. This could suggest the possibility that while these drugs do 
mitigate the risk of lymphoma arising from immunostimulation, they may open 
the door for lymphoma to arise in a background of immunosuppression, thus 
negating what would otherwise be a protective effect. It has also been suggested 
that abating inflammation in autoimmune disease is not entirely sufficient to 
avoid lymphoma development, and that more targeted therapies would perhaps 
help to elucidate the specific pathways leading to lymphomagenesis. This will be 
a critical future direction of research and drug development, thereby allowing 
targeting and interruption of the most critical shared pathways of RA 
inflammation and lymphomagenesis. 
Two recent studies in laboratory animals targeted pathways of 
inflammation other than cytokines and immunologic cells. One by Miotla et al. 
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targeted the EGF receptor and synovial angiogenesis and thereby reduced 
arthritis in experimental animals. [33] The other, by Vanniasinghe et al. used 
engineered targeted liposomes to deliver anti-rheumatic drugs directly to the 
synovial-like fibroblasts, also producing improvement in arthritis. [34] It remains 
to be seen how well these novel therapeutic ideas translate to human therapies, 
but it is reassuring that these new, divergent ideas are being explored. 
Personalized medicine approaches, including the expanding use of patient 
DNA sequencing, will enable a better understanding of the genetic basis and 
pathogenesis of RA. In this way it will likely bring to the forefront the most 
efficient means of treating RA patients individually. By enabling the assessment 
of unique disease characteristics between patients and clarifying the 
heterogeneous molecular pathways causing variations in disease, it may be 
possible to tailor treatment to further minimize risk of lymphoma and maximize 
the benefit of symptomatic relief.  
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